Investors hope Par Pharmaceutical
What analysts say:
- Buy, sell, or hold?: The majority of analysts back Par Pharmaceutical as a buy. But with 66.7% of analysts rating it a buy, Par Pharmaceutical is still below the mean analyst rating of its nearest 10 competitors, which average 67.9% buys. Analysts like Par Pharmaceutical better than competitor Mylan Laboratories overall. Out of 17 analysts, 11 rate Mylan Laboratories a buy compared to six of nine for Par Pharmaceutical. Analysts still rate the stock a moderate buy, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $210 million in revenue this quarter. That would represent a decline of 10.4% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.74 per share. Estimates range from $0.68 to $0.77.
What our community says:
CAPS All-Stars are solidly behind the stock with 91.8% giving it an "outperform" rating. The community at large agrees with the All-Stars with 86.8% assigning it a rating of "outperform." Fools are gung-ho about Par Pharmaceutical, though the message boards have been quiet lately with only 85 posts in the past 30 days. Despite the majority sentiment in favor of Par Pharmaceutical, the stock has a middling CAPS rating of three out of five stars.
Revenue has fallen for the past three quarters.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Par Pharmaceutical now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.